Arrowhead Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Leads in Yearly Revenue?

Biotech Rivals: Arrowhead vs. Dynavax in Revenue Growth

__timestampArrowhead Pharmaceuticals, Inc.Dynavax Technologies Corporation
Wednesday, January 1, 201417500011032000
Thursday, January 1, 20153820004050000
Friday, January 1, 201615833311043000
Sunday, January 1, 201731407709327000
Monday, January 1, 2018161423218198000
Tuesday, January 1, 201916879557735219000
Wednesday, January 1, 20208799206646551000
Friday, January 1, 2021138287000439442000
Saturday, January 1, 2022243231000722683000
Sunday, January 1, 2023240735000232284000
Monday, January 1, 20243551000
Loading chart...

Infusing magic into the data realm

Arrowhead Pharmaceuticals vs. Dynavax Technologies: A Revenue Showdown

In the competitive landscape of biotechnology, Arrowhead Pharmaceuticals and Dynavax Technologies have been vying for dominance in revenue growth. Over the past decade, Dynavax has shown a remarkable surge, especially between 2021 and 2022, where its revenue skyrocketed by over 64%, reaching a peak of approximately $723 million. This impressive growth can be attributed to its strategic focus on vaccine development, particularly during the global health crisis.

Conversely, Arrowhead Pharmaceuticals has demonstrated steady growth, with its revenue peaking at around $243 million in 2022. Despite a slight dip in 2023, Arrowhead's innovative approach in RNA interference therapeutics continues to hold promise.

While Dynavax leads in recent revenue figures, Arrowhead's consistent performance and potential for innovation make this a rivalry to watch. As the biotech industry evolves, both companies are poised to make significant impacts.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025